AFM
SMMT icon

Anson Funds Management’s Summit Therapeutics SMMT Stock Holding History

Anson Funds Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-941,908
Closed -$7.35M – 200
2024
Q2 		$7.35M Buy
+941,908
New +$5.09M 0.88% 20

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Anson Funds Management's SMMT Position: Q3 2024 in Review

Anson Funds Management sold out of Summit Therapeutics (SMMT) in Q3 2024, closing a stake of 941,908 shares — an estimated $7.35M sold.

Anson Funds Management first reported a position in SMMT in Q2 2024 and held it in 1 quarter. The position peaked at $7.35M in Q2 2024. 166 funds tracked by Wall St. Rank hold SMMT as of Q3 2024.

  • Anson Funds Management reported no remaining Summit Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Anson Funds Management sold 941,908 Summit Therapeutics shares in Q3 2024, an estimated $7.35M.
  • Anson Funds Management first reported a position in Summit Therapeutics in Q2 2024 and held it in 1 quarter.
  • Anson Funds Management's Summit Therapeutics position peaked at $7.35M in Q2 2024.
  • 166 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2024.

Based on Anson Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.